Diode Laser Treatment of Human Prostates
Journal of Lasers in Medical Sciences,
Vol. 3 No. 1 (2012),
14 March 2012
,
Page 1-5
Abstract
INTRODUCTION: Laser-assisted vaporization of prostate tissue by means of the potassiumtitanyl- phosphate (KTP) laser is in clinical use. Alternative laser sources are available but are lacking clinical experience.The 980 nm wavelength diode laser provides good hemostasis, in addition to a more rapid ablation rate. The aim of this study is approving the capability, feasibility, and good post-operative outcome of vaporization of prostate by means of a diode laser in a long-term follow up.METHODS: The light (980 nm, 100 W) of a diode laser was transmitted to prostate tissue. The study included 70 men suffering from bladder outlet obstruction due to benign prostatic hyperplasia (BPH). The prostatic lobes were vaporized within the prostatic capsule. Post-operative outcome and voiding were evaluated during a follow-up period of 24 months.
RESULTS: During surgery, no significant blood loss or any fluid absorption occurred. Catheters were removed in the 20.1±4.6 hours. All patients except two were satisfied with their voiding outcome. After removing the catheter, the mean peak urine flow rate significantly increased from 6.8±2.5 ml/s pre-operatively to 15.6±3.1 ml/s postoperatively. No evidence of urgency, dysuria, hematuria, or incontinence was observed. Four patients required re-catheterization, and two of them needed consecutive TURP. After a 1- month, as well as after a 6-month, a 12-mouth, and a 1-year follow-up, all patients were still satisfied with the outcome.
CONCLUSION: This long term experience showed that 100 W-980 nm-diode-laser vaporization prostatectomy was feasible and appeared to be safe and effective for quickly relieving bladder outlet obstruction due to BPH.
- BPH
- laser
- semiconductor
- diode laser
- ablation
How to Cite
References
Einstein A. ZurQuantentheorie der Strahlung [On the Quantum Mechanics of Radiation]. Phys Z 1917; 18:121– 8. German.
Maiman TH. Stimulated optical radiation in ruby. Nat 1960; 187:493–4.
White AD, Rigden JD. Continuous gas maser operation in the visible. Proc IRE 1962;50:1697–703.
Hofstetter A, Alarcon-Hofstetter A. [Treatment of prostatic tumors with interstitial thermocoagulation with neodymium-YAG] (a new treatment in minimally invasive surgery). Arch Esp Urol 1993; 46(4):317–9. Spanish.
Costello AJ, Bowsher WG, Bolton DM, Braslis KG, BurtJ. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 1992;69(6):603–8.
Malek RS, Barrett DM, Kuntzman RS. High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 h later. Urology 1998; 51(2):254–6.
Reich O, Bachmann A, Schneede P, Zaak D, Sulser T, Hofstetter A. Experimental comparison of high power(80 W) potassium titanyl phosphate laser vaporization and transurethral resection of the prostate. J Urol 2004;171(6 Pt 1):2502–4.
Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T. High power (80 W) potassium-titanylphosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005; 173(1):158–60.
Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol 2000;163(6): 1730-3.
Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: a short term prospective randomized trial. Urol 2008;71(2):247-51.
Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3years. BJU Int 2006; 97(6):1229-33.
Hermanns T, Sulser T, Fatzer M, Baumgartner MK, Rey JM, Sigrist MW, et al. Laser fibre deterioration and loss of power output during photo-selective 80-w potassiumtitanyl- phosphate laser vaporisation of the prostate. Eur Urol 2009 Mar;55(3):679-85.
Wendt-Nordahl G, Huckele S, Honeck P, Alken P, Knoll T, Michel MS, et al. 980-nm Diode laser: a novel laser technology for vaporization of the prostate. Eur Urol 2007; 52(6):1723-8.
Ogan K, Wilhelm D, Lindberg G, Lotan Y, Napper C, Hoopman J, et al. Laparoscopic partial nephrectomy with a diode laser: porcine results. J Endourol 2002; 16(10):749-53.
Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005; 174(4 Pt 1):1344–8.
Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46(5):547– 54.
Kaplan SA. AUA guidelines and their impact on the management of BPH: an update. Rev Urol 2004;6(Suppl 9):S46–52.
Reich O, Seitz M, Gratzke C, Schlenker B, Bachmann A, Stief C. [ Benign prostatic syndrome (BPS). Ablative treatments]. Urologe A 2006; 45(6):769–80. German.
Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M, et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol 2004;172(5Pt 1):1926–9.
Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol 2006;49(1):87–91.
Bachmann A, Schürch L, Ruszat R, Wyler SF, Seifert HH, Müller A, et al. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol 2005; 48(6): 965–71.
- Abstract Viewed: 538 times
- PDF Downloaded: 680 times